Breast Cancer

You may be eligible to participate if:  You have been diagnosed with stage II-III breast cancer within the last 12 months  You have completed surgery and chemotherapy (if applicable)  You are interested in losing weight and have a body mass index (or BMI) greater than 27 kg/m2  You would like to receive information about health topics  You are willing to be randomly assigned (like a flip of a coin) to one of two groups

 You are currently receiving or have completed 4 cycles of dose dense AC (Adriamycin/Cyclophosphamide) chemotherapy treatment.  Your blood counts meet the study criteria.  You are 18 to 64 years of age. You may not be eligible to participate if:  You had at least one episode of fever and neutropenia (low white blood cell counts) during the AC treatment.  You are receiving any investigational agents.  You are receiving any prohibited medications.  You are pregnant or nursing.  You have received other chemotherapy regimens in the last 5 years.

• Women or men with node positive, HER2 negative, stage II or III breast carcinoma within one year of diagnosis and free of recurrence. •If any chemotherapy and/or endocrine therapy the last dose must be at least 60 days prior to study registration. Concurrent hormonal therapy will be allowed. • Regular NSAID/aspirin use (defined as ≥ 5 days per week) is allowed if aspirin and/or NSAIDs are stopped for one year prior to study entry and throughout the study period. •Participants will be encouraged to use acetaminophen for minor pain and fever. •Patients must be enrolled within 1 year after diagnosis. •Age > 18 and < 70 years of age. •Platelet count ≥ 100,000/mm3 Exclusions: •No history of GI bleeding requiring a blood transfusion, endoscopic or operative intervention. • No history of any prior stroke • No concurrent anticoagulation with warfarin or heparin or clopidogrel or oral direct thrombin inhibitors. • No history of atrial fibrillation or myocardial infarction. • No history of grade 4 hypertension. •No chronic (duration >30 days) daily use of oral steriods. • No known allergy to aspirin. • No other cancer of any type within the past 5 years other than breast cancer, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. • Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin use.

You may be eligible to participate if:
 You have been diagnosed with stage II-III breast cancer within the last 12 months
 You have completed surgery and chemotherapy (if applicable)
 You are interested in losing weight and have a body mass index (or BMI) greater than 27 kg/m2

 You would like to receive information about health topics

 You are willing to be randomly assigned (like a flip of a coin) to one of two groups

 You are currently receiving or have completed 4 cycles of dose dense AC (Adriamycin/Cyclophosphamide) chemotherapy treatment.

 Your blood counts meet the study criteria.

 You are 18 to 64 years of age.

You may not be eligible to participate if:

 You had at least one episode of fever and neutropenia (low white blood cell counts) during the AC treatment.

 You are receiving any investigational agents.

 You are receiving any prohibited medications.

 You are pregnant or nursing.

 You have received other chemotherapy regimens in the last 5 years.

• Women or men with node positive, HER2 negative, stage II or III breast carcinoma within one year of diagnosis and free of recurrence. •If any chemotherapy and/or endocrine therapy the last dose must be at least 60 days prior to study registration. Concurrent hormonal therapy will be allowed. • Regular NSAID/aspirin use (defined as ≥ 5 days per week) is allowed if aspirin and/or NSAIDs are stopped for one year prior to study entry and throughout the study period. •Participants will be encouraged to use acetaminophen for minor pain and fever. •Patients must be enrolled within 1 year after diagnosis. •Age > 18 and < 70 years of age. •Platelet count ≥ 100,000/mm3 Exclusions: •No history of GI bleeding requiring a blood transfusion, endoscopic or operative intervention. • No history of any prior stroke • No concurrent anticoagulation with warfarin or heparin or clopidogrel or oral direct thrombin inhibitors. • No history of atrial fibrillation or myocardial infarction. • No history of grade 4 hypertension. •No chronic (duration >30 days) daily use of oral steriods. • No known allergy to aspirin. • No other cancer of any type within the past 5 years other than breast cancer, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. • Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin use.